These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 16652032

  • 1. Mixed patterns of changes in central and peripheral fat following initiation of antiretroviral therapy in a randomized trial.
    Mulligan K, Parker RA, Komarow L, Grinspoon SK, Tebas P, Robbins GK, Roubenoff R, Dubé MP.
    J Acquir Immune Defic Syndr; 2006 Apr 15; 41(5):590-7. PubMed ID: 16652032
    [Abstract] [Full Text] [Related]

  • 2. Long-term body fat outcomes in antiretroviral-naive participants randomized to nelfinavir or efavirenz or both plus dual nucleosides. Dual X-ray absorptiometry results from A5005s, a substudy of Adult Clinical Trials Group 384.
    Dubé MP, Komarow L, Mulligan K, Grinspoon SK, Parker RA, Robbins GK, Roubenoff R, Tebas P, Adult Clinical Trials Group 384.
    J Acquir Immune Defic Syndr; 2007 Aug 15; 45(5):508-14. PubMed ID: 17589373
    [Abstract] [Full Text] [Related]

  • 3. Glucose metabolism, lipid, and body fat changes in antiretroviral-naive subjects randomized to nelfinavir or efavirenz plus dual nucleosides.
    Dubé MP, Parker RA, Tebas P, Grinspoon SK, Zackin RA, Robbins GK, Roubenoff R, Shafer RW, Wininger DA, Meyer WA, Snyder SW, Mulligan K.
    AIDS; 2005 Nov 04; 19(16):1807-18. PubMed ID: 16227788
    [Abstract] [Full Text] [Related]

  • 4. Stavudine but not didanosine as part of HAART contributes to peripheral lipoatrophy: a substudy from the Antiretroviral Regimen Evaluation Study (ARES).
    Lowe SH, Hassink EA, van Eck-Smit BL, Borleffs JC, Lange JM, Reiss P.
    HIV Clin Trials; 2007 Nov 04; 8(5):337-44. PubMed ID: 17956835
    [Abstract] [Full Text] [Related]

  • 5. Effects of potent antiretroviral therapy on free testosterone levels and fat-free mass in men in a prospective, randomized trial: A5005s, a substudy of AIDS Clinical Trials Group Study 384.
    Dubé MP, Parker RA, Mulligan K, Tebas P, Robbins GK, Roubenoff R, Grinspoon SK.
    Clin Infect Dis; 2007 Jul 01; 45(1):120-6. PubMed ID: 17554712
    [Abstract] [Full Text] [Related]

  • 6. Fat Mass Ratio in Brazilian HIV-infected Patients Under Antiretroviral Therapy and Its Relationship With Anthropometric Measurents.
    Bicudo Bruno Nogueira A, Abreu JM, Mesquita Villela M, Boracini Sanchez AE, Silva Chaves B, Setubal S, Coca Velarde LG, Cruz Filho RAD, Balarini Lima GA, Soares DV.
    J Clin Densitom; 2020 Jul 01; 23(4):623-629. PubMed ID: 30545683
    [Abstract] [Full Text] [Related]

  • 7. A randomized comparative trial of continued zidovudine/lamivudine or replacement with tenofovir disoproxil fumarate/emtricitabine in efavirenz-treated HIV-1-infected individuals.
    Fisher M, Moyle GJ, Shahmanesh M, Orkin C, Kingston M, Wilkins E, Ewan J, Liu H, Ebrahimi R, Reilly G, SWEET (Simplification With Easier Emtricitabine Tenofovir) group UK.
    J Acquir Immune Defic Syndr; 2009 Aug 15; 51(5):562-8. PubMed ID: 19561519
    [Abstract] [Full Text] [Related]

  • 8. Abacavir substitution for nucleoside analogs in patients with HIV lipoatrophy: a randomized trial.
    Carr A, Workman C, Smith DE, Hoy J, Hudson J, Doong N, Martin A, Amin J, Freund J, Law M, Cooper DA, Mitochondrial Toxicity (MITOX) Study Group.
    JAMA; 2002 Jul 10; 288(2):207-15. PubMed ID: 12095385
    [Abstract] [Full Text] [Related]

  • 9. Hemochromatosis gene polymorphisms, mitochondrial haplogroups, and peripheral lipoatrophy during antiretroviral therapy.
    Hulgan T, Tebas P, Canter JA, Mulligan K, Haas DW, Dubé M, Grinspoon S, Robbins GK, Motsinger AA, Kallianpur AR, AIDS Clinical Trials Group 384 and A5005s Study Teams.
    J Infect Dis; 2008 Mar 15; 197(6):858-66. PubMed ID: 18419350
    [Abstract] [Full Text] [Related]

  • 10. Contribution of genetic background and antiretroviral therapy to body fat changes in antiretroviral-naive HIV-infected adults.
    Egaña-Gorroño L, Martínez E, Pérez I, Escribà T, Domingo P, Gatell JM, Arnedo M.
    J Antimicrob Chemother; 2014 Nov 15; 69(11):3076-84. PubMed ID: 25185137
    [Abstract] [Full Text] [Related]

  • 11. Effects of discontinuing stavudine or protease inhibitor therapy on human immunodeficiency virus-related fat redistribution evaluated by dual-energy x-ray absorptiometry.
    Tavassoli N, Bagheri H, Sommet A, Delpierre C, Marion-Latard F, Massip P, Aquilina C, Bonnet E, Obadia M, Labau E, Montastruc JL, Bernard J.
    Pharmacotherapy; 2006 Feb 15; 26(2):154-61. PubMed ID: 16466321
    [Abstract] [Full Text] [Related]

  • 12. Lipid levels and changes in body fat distribution in treatment-naive, HIV-1-Infected adults treated with rilpivirine or Efavirenz for 96 weeks in the ECHO and THRIVE trials.
    Tebas P, Sension M, Arribas J, Duiculescu D, Florence E, Hung CC, Wilkin T, Vanveggel S, Stevens M, Deckx H, ECHO and THRIVE Study Groups.
    Clin Infect Dis; 2014 Aug 01; 59(3):425-34. PubMed ID: 24729492
    [Abstract] [Full Text] [Related]

  • 13. Pronounced lipoatrophy in HIV-infected men receiving HAART for more than 6 years compared with the background population.
    Hansen AB, Lindegaard B, Obel N, Andersen O, Nielsen H, Gerstoft J.
    HIV Med; 2006 Jan 01; 7(1):38-45. PubMed ID: 16313291
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study.
    Boyd MA, Amin J, Mallon PW, Kumarasamy N, Lombaard J, Wood R, Chetchotisakd P, Phanuphak P, Mohapi L, Azwa I, Belloso WH, Molina JM, Hoy J, Moore CL, Emery S, Cooper DA, SECOND-LINE Study Group.
    Lancet HIV; 2017 Jan 01; 4(1):e13-e20. PubMed ID: 27815068
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Longitudinal anthropometric changes in HIV-infected and HIV-uninfected men.
    Brown T, Wang Z, Chu H, Palella FJ, Kingsley L, Witt MD, Dobs AS.
    J Acquir Immune Defic Syndr; 2006 Nov 01; 43(3):356-62. PubMed ID: 16980910
    [Abstract] [Full Text] [Related]

  • 20. Switching from zidovudine/lamivudine to tenofovir/emtricitabine improves fat distribution as measured by fat mass ratio.
    Martínez E, Ribera E, Clotet B, Estrada V, Sanz J, Berenguer J, Rubio R, Pulido F, Larrousse M, Curran A, Negredo E, Arterburn S, Ferrer P, Álvarez ML.
    HIV Med; 2015 Jul 01; 16(6):370-4. PubMed ID: 25496141
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.